Physician profile
Michelle Powell
NPI 1154350577
$34,129.90
in general payments reported to CMS, 2019-2025
15 companies · $528 in 2025
The $528 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $7,664 · 2020: $1,970 · 2021: $487 · 2022: $22K · 2023: $786 · 2024: $1,004 · 2025: $528.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,318.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,318.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viiv Healthcare Company | $22,335.07 | 2019-2025 | Apretude, Dovato, Cabenuva |
| Gilead Sciences, INC. | $10,393.40 | 2019-2025 | Biktarvy |
| Merck Sharp & Dohme LLC | $459.09 | 2019-2024 | Pifeltro, Delstrigo, Dificid |
| Janssen Biotech, INC. | $441.07 | 2021-2023 | Symtuza |
| Janssen Products, LP | $128.99 | 2021-2022 | |
| Pfizer INC. | $94.58 | 2019-2024 | |
| Emd Serono, INC. | $74.97 | 2023-2024 | Serostim |
| Amgen INC. | $47.76 | 2021-2023 | Otezla, Repatha |
| Theratechnologies INC. | $35.33 | 2024 | Trogarzo, Egrifta |
| Lilly USA, LLC | $27.18 | 2022-2023 | Mounjaro |
| Verity Pharmaceuticals INC. | $23.19 | 2024 | Tlando |
| Redhill Biopharma INC. | $22.74 | 2020 | |
| Exact Sciences Corporation | $17.50 | 2024 | Cologuard Collection Kit |
| Dynavax Technologies Corporation | $15.51 | 2022 | |
| Napo Pharmaceuticals INC | $13.52 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michelle Powell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.